A PHASE 1, OPEN-LABEL TRIAL TO ASSESS THE SAFETY AND PHARMACOKINETICS OF MULTIPLE ASCENDING DOSES OF DT-818 IN HEALTHY VOLUNTEERS AND PARTICIPANTS WITH MYOTONIC DYSTROPHY TYPE 1

Registry ID

DTX-818-101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

DESIGN THERAPEUTICS, INC.

Start date

2026-06-24

Last update

2026-01-14

Conditions

• MYOTONIC DYSTROPHY

Related clinical trials

• A GLOBAL PHASE 3 OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF INTRAVENOUS AOC 1001 FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1
• AN OPEN-LABEL EXTENSION STUDY EVALUATING SAFETY AND PHARMACOKINETICS IN PARTICIPANTS WITH MYOTONIC DYSTROPHY TYPE 1 (FREEDOM-OLE)
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS AOC 1001 FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1
• A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-ASCENDING DOSE STUDY OF PGN-EDODM1 IN ADULT PARTICIPANTS WITH MYOTONIC DYSTROPHY TYPE 1 (FREEDOM2-DM1)
• A PHASE 1/2A DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-DM1 (SRP-1003) IN SUBJECTS WITH TYPE 1 MYOTONIC DYSTROPHY WHO ARE 18 TO 65 YEARS
• A PHASE 1/2A DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-DM1 IN SUBJECTS WITH TYPE 1 MYOTONIC DYSTROPHY WHO ARE 18 TO 65 YEARS

View on source registry